Quarterly Report 2018 Q3

November 20, 2018

An Overview of the Prometic Quarterly Report

  • Extension of maturity dates of Line of Credit and OID Loans to September 2024

  • Implementation of cost control measures to significantly reduce operational burn and extend cash runway

  • Substantial reduction in R&D costs of up to $30 million in 2019 versus 2018

  • Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manufacturing process  

  • Q3 revenues of $12.3 million

  • Granted Rare Pediatric Disease Designation by FDA for PBI-4050 to treat Alström Syndrome

No Previous Flipbooks

Next Flipbook
Annual Report 2017
Annual Report 2017

Prometic has during 2017, continued its transition that has transformed the company into a biopharmaceutica...